Intervertebral disc degeneration (IVDD) is a progressive degenerative disorder of the spine characterized by oxidative stress and cellular dysfunction. Current clinical treatments for IVDD include surgical procedures, such as discectomy and spinal fusion, as well as pharmacological therapies using analgesics and anti‐inflammatory agents. However, these strategies primarily offer symptomatic relief and do not address the underlying causes of IVDD. Targeting oxidative stress has emerged as a promising therapeutic approach, yet its effectiveness remains limited. To overcome this limitation, an antioxidant carbon dot of selenomethionine (Se‐Met‐CD) is developed for efficient IVDD therapy. Se‐Met‐CD effectively scavenges excess reactive oxygen species (ROS), alleviates oxidative stress, and restores intracellular redox homeostasis in nucleus pulposus cells. Se‐Met‐CD exhibits an antioxidant capacity 3.1 times that of its precursor, Se‐Met, when compared at the same concentration. In hydrogen peroxide (H 2 O 2 )‐treated nucleus pulposus cells, Se‐Met‐CD significantly reduces intracellular ROS levels to 17.7% of those in untreated control cells. In a puncture‐induced IVDD rat model, Se‐Met‐CD demonstrates remarkable therapeutic efficacy by significantly attenuating disc degeneration, reflected in lower Pfirrmann and histological scores. These results underscore the potential of Se‐Met‐CD to treat IVDD by scavenging ROS, restoring antioxidant balance, and modulating the local microenvironments.
Timely therapeutic interventions for acute spinal cord injury (SCI) are critical for enhancing long‐term neurological and functional outcomes by limiting injury progression. However, current clinical strategies, such as methylprednisolone (MS) shock therapy and spinal decompression surgery, often yield suboptimal results. Moreover, MS administration is linked to severe systemic side effects, including pneumonia and gastrointestinal bleeding, while determining the optimal timing for decompression surgery remains challenging. Therefore, developing innovative therapeutic approaches is essential. Biomaterials, with their advanced drug delivery capabilities and unique biochemical properties, modulate cell behaviors and regulate the microenvironments of injured spinal cord, offering a promising treatment avenue for acute SCI. This review highlights the dynamic changes in SCI tissue during the initial phases and examines cutting‐edge biomaterial‐based emergency interventions, including the limitation of inflammation, reduction of excitotoxicity, restoration of the blood−spinal cord barrier, and inhibition of scar formation. Additionally, it addresses the challenges and opportunities of translating these innovations from basic research to clinical practice, thereby guiding future developments in clinically viable biomaterials.
The microenvironments play a crucial role in secondary injury following spinal cord injury (SCI). Deterioration of the microenvironments, including oxidative stress, inflammation, and excitotoxicity, exacerbates SCI. However, due to the complexity of these microenvironments, synergistic modulation of multiple factors remains challenging. In this study, we developed a reactive oxygen species (ROS) responsive nanoformulation system based on a methoxy poly(ethylene glycol)-block-poly(L-methionine-co-L-glutamic acid) copolymer (PME) and loaded it with minocycline (PME@Mino) to promote SCI repair. This nanoformulation was administered intravenously, accumulating at the lesion site where PME@Mino was exposed to ROS, triggering the release of minocycline. Through the synergistic modulation of multiple microenvironment factors, including reduction of oxidative stress, regulation of pro-inflammatory M1 macrophages polarization to anti-inflammatory M2 macrophages, and reduction of calcium ion influx, PME@Mino achieved neuronal and myelin protection. This study highlights advanced approaches for modulating microenvironments using nanoscale treatments for SCI.